JP2008512348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512348A5 JP2008512348A5 JP2007518228A JP2007518228A JP2008512348A5 JP 2008512348 A5 JP2008512348 A5 JP 2008512348A5 JP 2007518228 A JP2007518228 A JP 2007518228A JP 2007518228 A JP2007518228 A JP 2007518228A JP 2008512348 A5 JP2008512348 A5 JP 2008512348A5
- Authority
- JP
- Japan
- Prior art keywords
- halogen
- aryl
- lower alkyl
- optionally
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 238000009472 formulation Methods 0.000 claims 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 206010046851 Uveitis Diseases 0.000 claims 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 208000006673 asthma Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 4
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 4
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 201000009961 allergic asthma Diseases 0.000 claims 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 208000024693 gingival disease Diseases 0.000 claims 3
- 208000007565 gingivitis Diseases 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 208000028169 periodontal disease Diseases 0.000 claims 3
- 201000001245 periodontitis Diseases 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 150000003839 salts Chemical group 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- -1 — (CH 2 ) n —CF 3 Chemical group 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010022557 Intermediate uveitis Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 206010036346 Posterior capsule opacification Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010010180 Renal failure complications Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 206010041925 Staphylococcal infections Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010052568 Urticaria chronic Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010057469 Vascular stenosis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000009101 diabetic angiopathy Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000007407 panuveitis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 0 ***N*c1ccccc1 Chemical compound ***N*c1ccccc1 0.000 description 9
- VTZOSIRDOPNJJJ-UHFFFAOYSA-N CN(C(c(cc1Cl)ccc1Cl)=O)C1=CC=C(C[IH][N](C)(C)C2CCCCC2)CC1 Chemical compound CN(C(c(cc1Cl)ccc1Cl)=O)C1=CC=C(C[IH][N](C)(C)C2CCCCC2)CC1 VTZOSIRDOPNJJJ-UHFFFAOYSA-N 0.000 description 1
- ZFBNYWPJZDVEFB-UHFFFAOYSA-N C[N](C)(Cc(cc1)ccc1NC(C(C1)C=CC(Cl)=C1Cl)=O)C1C2CCC1C2 Chemical compound C[N](C)(Cc(cc1)ccc1NC(C(C1)C=CC(Cl)=C1Cl)=O)C1C2CCC1C2 ZFBNYWPJZDVEFB-UHFFFAOYSA-N 0.000 description 1
- KZWVIZCCHJBLFX-UHFFFAOYSA-O Cc(c(Cl)c1)ccc1C(Nc1ccc(C[N+](C)(C)C2CCCCC2)cc1)=O Chemical compound Cc(c(Cl)c1)ccc1C(Nc1ccc(C[N+](C)(C)C2CCCCC2)cc1)=O KZWVIZCCHJBLFX-UHFFFAOYSA-O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58292904P | 2004-06-25 | 2004-06-25 | |
| US60/582,929 | 2004-06-25 | ||
| PCT/US2005/022034 WO2006012135A1 (en) | 2004-06-24 | 2005-06-22 | Quaternary salt ccr2 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008512348A JP2008512348A (ja) | 2008-04-24 |
| JP2008512348A5 true JP2008512348A5 (enExample) | 2008-08-07 |
| JP5137572B2 JP5137572B2 (ja) | 2013-02-06 |
Family
ID=35045442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518228A Expired - Fee Related JP5137572B2 (ja) | 2004-06-24 | 2005-06-22 | 第四級塩であるｃｃｒ２アンタゴニスト |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7799824B2 (enExample) |
| EP (1) | EP1765803B1 (enExample) |
| JP (1) | JP5137572B2 (enExample) |
| KR (1) | KR101229416B1 (enExample) |
| CN (1) | CN101010312B (enExample) |
| AR (1) | AR049652A1 (enExample) |
| AU (1) | AU2005267385B2 (enExample) |
| BR (1) | BRPI0512623A (enExample) |
| CA (1) | CA2571587C (enExample) |
| EA (1) | EA012784B1 (enExample) |
| EC (1) | ECSP067116A (enExample) |
| ES (1) | ES2573845T3 (enExample) |
| IL (1) | IL180197A0 (enExample) |
| MX (1) | MX2007000036A (enExample) |
| NI (1) | NI200600319A (enExample) |
| NO (1) | NO20070387L (enExample) |
| NZ (1) | NZ552173A (enExample) |
| TW (1) | TWI407957B (enExample) |
| UA (1) | UA85597C2 (enExample) |
| WO (1) | WO2006012135A1 (enExample) |
| ZA (1) | ZA200700677B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ552173A (en) | 2004-06-25 | 2010-07-30 | Janssen Pharmaceutica Nv | Quaternary salt CCR2 antagonists |
| EP2097452A1 (en) * | 2006-12-14 | 2009-09-09 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
| WO2008131481A1 (en) * | 2007-04-26 | 2008-11-06 | Fibrotech Therapeutics Pty Ltd | Treatment of mesangioproliferative diseases |
| CA2687931C (en) | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| US8016912B2 (en) | 2007-09-14 | 2011-09-13 | Barrick Gold Corporation | Process for recovering platinum group metals using reductants |
| US8093428B2 (en) * | 2007-10-26 | 2012-01-10 | Janssen Pharmaceutica N.V. | Synthesis of quaternary salt compounds |
| US8168829B2 (en) * | 2007-10-26 | 2012-05-01 | Janssen Pharmaceutica N.V. | Synthesis of quaternary salt compounds |
| TW200927740A (en) * | 2007-11-13 | 2009-07-01 | Bial Portela & Ca Sa | Process |
| KR100954138B1 (ko) * | 2007-12-31 | 2010-04-20 | 부산대학교 산학협력단 | 지방조직 유래 줄기세포를 함유하는 알레르기 비염 또는천식 예방 및 치료제 |
| CN101481323B (zh) * | 2008-01-11 | 2013-11-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯并环庚烯类衍生物、其制备方法及医药用途 |
| CN103724328B (zh) | 2008-12-19 | 2015-10-14 | 贝林格尔.英格海姆国际有限公司 | 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺 |
| CN105153188B (zh) | 2009-10-22 | 2018-06-01 | 法博太科制药有限公司 | 抗纤维化剂的稠环类似物 |
| PL2513093T3 (pl) | 2009-12-17 | 2015-03-31 | Centrexion Therapeutics Corp | Nowi antagoniści receptora CCR2 i ich zastosowanie |
| EP2569295B1 (en) | 2010-05-12 | 2014-11-19 | Boehringer Ingelheim International GmbH | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| JP2013526507A (ja) | 2010-05-12 | 2013-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用 |
| US8841313B2 (en) | 2010-05-17 | 2014-09-23 | Boehringer Ingelheim International Gmbh | CCR2 antagonists and uses thereof |
| JP5636094B2 (ja) | 2010-05-25 | 2014-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２受容体アンタゴニスト |
| EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
| MX367469B (es) | 2010-06-07 | 2019-08-23 | Novomedix Llc | Compuestos furanilo y su uso. |
| WO2012012184A2 (en) * | 2010-06-30 | 2012-01-26 | Johnson & Johnson Vision Care, Inc. | Ophthalmic devices containing chemokine antagonists |
| EP2583965B1 (en) * | 2010-07-15 | 2017-01-25 | Takeda Pharmaceutical Company Limited | Heterocyclic ring compound |
| US10451897B2 (en) | 2011-03-18 | 2019-10-22 | Johnson & Johnson Vision Care, Inc. | Components with multiple energization elements for biomedical devices |
| WO2013009582A1 (en) | 2011-07-12 | 2013-01-17 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| WO2013010839A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Novel and selective ccr2 antagonists |
| US9812730B2 (en) | 2011-08-02 | 2017-11-07 | Johnson & Johnson Vision Care, Inc. | Biocompatible wire battery |
| US20140329809A1 (en) | 2011-10-28 | 2014-11-06 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| US8857983B2 (en) | 2012-01-26 | 2014-10-14 | Johnson & Johnson Vision Care, Inc. | Ophthalmic lens assembly having an integrated antenna structure |
| EP3338776A1 (en) | 2012-05-01 | 2018-06-27 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| US9715130B2 (en) | 2014-08-21 | 2017-07-25 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form separators for biocompatible energization elements for biomedical devices |
| US9599842B2 (en) | 2014-08-21 | 2017-03-21 | Johnson & Johnson Vision Care, Inc. | Device and methods for sealing and encapsulation for biocompatible energization elements |
| US9941547B2 (en) | 2014-08-21 | 2018-04-10 | Johnson & Johnson Vision Care, Inc. | Biomedical energization elements with polymer electrolytes and cavity structures |
| US10361404B2 (en) | 2014-08-21 | 2019-07-23 | Johnson & Johnson Vision Care, Inc. | Anodes for use in biocompatible energization elements |
| US10627651B2 (en) | 2014-08-21 | 2020-04-21 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers |
| US9383593B2 (en) | 2014-08-21 | 2016-07-05 | Johnson & Johnson Vision Care, Inc. | Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators |
| US10381687B2 (en) | 2014-08-21 | 2019-08-13 | Johnson & Johnson Vision Care, Inc. | Methods of forming biocompatible rechargable energization elements for biomedical devices |
| US10361405B2 (en) | 2014-08-21 | 2019-07-23 | Johnson & Johnson Vision Care, Inc. | Biomedical energization elements with polymer electrolytes |
| US9793536B2 (en) | 2014-08-21 | 2017-10-17 | Johnson & Johnson Vision Care, Inc. | Pellet form cathode for use in a biocompatible battery |
| AU2016287584B2 (en) | 2015-07-02 | 2020-03-26 | Centrexion Therapeutics Corporation | (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate |
| PT3416962T (pt) * | 2016-02-15 | 2021-07-23 | Sanofi Sa | Derivados de 6,7-di-hidro-5h-benzo[7]anuleno como moduladores do recetor de estrogénio |
| US10345620B2 (en) | 2016-02-18 | 2019-07-09 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices |
| CN109963848B (zh) | 2016-11-17 | 2022-07-05 | 赛诺菲 | 取代的n-(3-氟丙基)-吡咯烷化合物、其制备方法以及其治疗用途 |
| US11014873B2 (en) | 2017-02-03 | 2021-05-25 | Certa Therapeutics Pty Ltd. | Anti-fibrotic compounds |
| EP3434272A1 (en) | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| AU2019252676A1 (en) | 2018-04-11 | 2020-11-26 | Ohio State Innovation Foundation | Methods and compositions for sustained release microparticles for ocular drug delivery |
| JP2021534101A (ja) | 2018-08-09 | 2021-12-09 | ヴェルソー セラピューティクス， インコーポレイテッド | Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用 |
| KR20210057032A (ko) | 2018-09-07 | 2021-05-20 | 사노피 | 메틸 6-(2,4-디클로로페닐)-5-[4-[(3s)-1-(3-플루오로프로필)피롤리딘-3-일]옥시페닐]-8,9-디히드로-7h-벤조[7]아눌렌-2-카르복실레이트의 염 및 이의 제조 방법 |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| CN111808062B (zh) * | 2020-07-28 | 2022-09-13 | 遵义医科大学 | 一种蛇床子素磺酸酯类化合物及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0873476A (ja) * | 1994-07-04 | 1996-03-19 | Takeda Chem Ind Ltd | ホスホン酸誘導体およびそれを含んでなる医薬 |
| JP4416198B2 (ja) * | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
| CA2304959A1 (en) * | 1997-12-19 | 1999-07-01 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative |
| ZA9811576B (en) * | 1997-12-19 | 2000-06-19 | Takeda Chemical Industries Ltd | Anilide derivative, production and use thereof. |
| AU5301599A (en) | 1998-08-20 | 2000-03-14 | Takeda Chemical Industries Ltd. | Quaternary ammonium salts and their use |
| CA2353635A1 (en) | 1998-12-21 | 2000-06-29 | Takeda Chemical Industries, Ltd. | Anilide derivative, production and use thereof |
| JP2001058988A (ja) * | 1998-12-21 | 2001-03-06 | Takeda Chem Ind Ltd | アニリド誘導体、その製造法および用途 |
| JP2001026586A (ja) * | 1999-05-07 | 2001-01-30 | Takeda Chem Ind Ltd | 環状化合物およびその用途 |
| CA2373073A1 (en) * | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
| WO2001042224A1 (en) * | 1999-12-09 | 2001-06-14 | Mitsubishi Pharma Corporation | Carboxyamido derivatives |
| JP2004043432A (ja) * | 2002-04-19 | 2004-02-12 | Takeda Chem Ind Ltd | Ｈｉｖ感染予防剤 |
| AU2003235205A1 (en) * | 2002-04-19 | 2003-11-03 | Takeda Pharmaceutical Company Limited | Preventives for hiv infection |
| JP4145230B2 (ja) * | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| AU2005256507A1 (en) * | 2004-06-25 | 2006-01-05 | Basf Aktiengesellschaft | Triazolopyrimidine compounds and their use for controlling pathogenic fungi |
| NZ552173A (en) | 2004-06-25 | 2010-07-30 | Janssen Pharmaceutica Nv | Quaternary salt CCR2 antagonists |
-
2005
- 2005-06-22 NZ NZ552173A patent/NZ552173A/en not_active IP Right Cessation
- 2005-06-22 WO PCT/US2005/022034 patent/WO2006012135A1/en not_active Ceased
- 2005-06-22 US US11/159,018 patent/US7799824B2/en active Active
- 2005-06-22 KR KR1020077001484A patent/KR101229416B1/ko not_active Expired - Fee Related
- 2005-06-22 UA UAA200614021A patent/UA85597C2/ru unknown
- 2005-06-22 CN CN2005800286402A patent/CN101010312B/zh not_active Expired - Fee Related
- 2005-06-22 JP JP2007518228A patent/JP5137572B2/ja not_active Expired - Fee Related
- 2005-06-22 AU AU2005267385A patent/AU2005267385B2/en not_active Ceased
- 2005-06-22 ES ES05766641.4T patent/ES2573845T3/es not_active Expired - Lifetime
- 2005-06-22 EP EP05766641.4A patent/EP1765803B1/en not_active Expired - Lifetime
- 2005-06-22 BR BRPI0512623-1A patent/BRPI0512623A/pt not_active Application Discontinuation
- 2005-06-22 EA EA200700116A patent/EA012784B1/ru not_active IP Right Cessation
- 2005-06-22 MX MX2007000036A patent/MX2007000036A/es unknown
- 2005-06-22 CA CA2571587A patent/CA2571587C/en not_active Expired - Fee Related
- 2005-06-24 TW TW094121070A patent/TWI407957B/zh not_active IP Right Cessation
- 2005-06-24 AR ARP050102614A patent/AR049652A1/es not_active Application Discontinuation
-
2006
- 2006-12-19 IL IL180197A patent/IL180197A0/en unknown
- 2006-12-21 NI NI200600319A patent/NI200600319A/es unknown
- 2006-12-26 EC EC2006007116A patent/ECSP067116A/es unknown
-
2007
- 2007-01-22 NO NO20070387A patent/NO20070387L/no not_active Application Discontinuation
- 2007-01-24 ZA ZA200700677A patent/ZA200700677B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008512348A5 (enExample) | ||
| JP6964096B2 (ja) | ３−オキソ−２，６−ジフェニル−２，３−ジヒドロピリダジン−４−カルボキサミド類 | |
| KR101937501B1 (ko) | 치환된 2,3-디히드로이미다조[1,2-ｃ]퀴나졸린 염 | |
| KR102544847B1 (ko) | 4Ｈ-피롤로［3,2-ｃ］피리딘-4-온 유도체 | |
| JP2007505933A5 (enExample) | ||
| US6787555B2 (en) | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | |
| JP7669372B2 (ja) | 新規な化合物及びその使用 | |
| JP6804516B2 (ja) | 変異イソクエン酸デヒドロゲナーゼｉｄｈ１ ｒ１３２ｈの阻害剤 | |
| IL166855A (en) | Annals of compressed pyrimidine with azaleas that inhibit pi3k activity and drugs containing them. | |
| WO2011163594A2 (en) | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | |
| CN103003269B (zh) | 取代的杂环基苄基吡唑及其用途 | |
| JP2010529193A5 (enExample) | ||
| ES2437346T3 (es) | Procedimiento para la producción de derivado de diamina | |
| CN107921286A (zh) | 1h‑吡咯‑3‑胺类化合物 | |
| JP2004517099A5 (enExample) | ||
| JP2009526831A5 (enExample) | ||
| WO2006125180B1 (en) | Piperazine derivatives and their uses as therapeutic agents | |
| JP7338711B2 (ja) | Ｄｐアンタゴニスト | |
| JP2005508969A5 (enExample) | ||
| CN101061123A (zh) | 噻吩并吡啶酮化合物及治疗方法 | |
| JP5315336B2 (ja) | 精神疾患治療用の新規化合物とその調剤及び使用 | |
| JP2010514733A5 (enExample) | ||
| JP5960695B2 (ja) | パンテニルドコサヘキサエノアート、ならびに心血管疾患を治療および予防するためのその使用 | |
| WO2012130850A1 (de) | Gewebetargeting mit onkoziden verbrückten diphenylderivaten zur selektiven behandlung von sexualorgantumoren | |
| CN1678310A (zh) | 用于治疗良性和恶性肿瘤疾病的含有disorazole及其衍生物的药物 |